Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients

Journal of Medical Virology

Volumn 85, Issue 8, 2013, Pages 1321-1326

  Mata Marín, José A ^a,d   Méndez Cruz, René ^a,b   Arroyo Anduiza, Carla I ^a   Mata Marín, Luis A ^c   Gaytán Martínez, Jesús ^a   Asbún Bojalil, Juan ^d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c StJohannisstift Ev Krankenhaus   (Germany)

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Antiretroviral therapy; Endothelial damage; Patients infected with HIV

Indexed keywords

C REACTIVE PROTEIN; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; SELECTIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84879154489     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23624     Document Type: Article

References (22)

1. Arildsen H, Sørensen K, Ingerslev J, Ostergaard L, Laursen A. 2013. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 14:1-9.
2. Armstrong EJ, Morrow DA, Sabatine MS. 2006. Inflammatory biomarkers in acute coronary syndromes. Part II: Acute-phase reactants and biomarkers of endothelial cell activation. Circulation 113:e152-e155.
3. Carr A, Samaras K, Chisholm DJ, Cooper DA. 1998. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 352:1881-1883.
4. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. 2011. Abacavir use and cardiovascular disease events: A meta-analysis of published and unpublished data. AIDS 25:1993-2004.
5. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. 2003. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003.
6. de Gaetano-Donati K, Rabagliati R, Tumbarello M, Tacconelli E, Amore C, Cauda R, Lacoviello L. 2003. Increased soluble markers of endothelial dysfunction in HIV positive patients under highly active antiretroviral therapy. AIDS 17:765-768.
7. De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Sfara C, Madeddu G, Bonfanti P, CISAI Study Group. 2008. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. J Infect 57:33-40.
8. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD, Working Group 3. 2008. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 118:e36-e40.
9. Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P, D:A:D Study Group. 2004. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189:1056-1074.
10. Grinspoon SK. 2005. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 118(Suppl 2):23S-28S.
11. Grover SA, Coupal L, Gilmore N, Mukherjee J. 2005. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 95:586-591.
12. Kanmogne GD, Primeaux C, Grammas P. 2005. Induction of apoptosis endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 333:1107-1115.
13. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. 2009. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 10:79-87.
14. Lipshultz SE, Fisher SD, Lai WW, Miller TL. 2003. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17(Suppl 1):S96-S122.
15. Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C. 2003. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 38:549-556.
16. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
17. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, Harrill D, Tungsiripat M, Adell J, McComsey GA. 2009. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 49:1119-1127.
18. Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg H. 2005. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 150:933.31-933.e7.
19. Stein JH, Hadigan CM, Brown TT, Chadwick E, Feinberg J, Friis-Møller N, Ganesan A, Glesby MJ, Hardy D, Kaplan RC, Kim P, Lo J, Martinez E, Sosman JM, Working Group 6. 2008. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation 118:e54-e60.
20. Varriale P, Saravi G, Hernandez E, Carbon F. 2004. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 147:55-59.
21. Worm SW, Sabin S, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Fontas E, Weller I, Phillips A, Lundgren J. 2010. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 201:318-330.
22. Zhong DS, Lu XH, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C. 2002. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22:1758-1760.